

## Retraction

# Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies

Janghyun Lee<sup>1,†</sup>, Eun-Byeol Park<sup>2,†</sup>, Jiyoun Min<sup>2,†</sup>, Si-Eun Sung<sup>1,†</sup>, Yejin Jang<sup>3</sup>, Jin Soo Shin<sup>3</sup>, Dongmin Chun<sup>2</sup>, Ki-Hun Kim<sup>1</sup>, Jihyun Hwang<sup>1</sup>, Mi-Kyung Lee<sup>1</sup>, Yun Young Go<sup>3</sup>, Dohyeong Kwon<sup>2</sup>, Meehyein Kim<sup>3,\*</sup>, Suk-Jo Kang<sup>2,\*</sup> and Byong-Seok Choi<sup>1,\*</sup>

<sup>1</sup>Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, South Korea, <sup>2</sup>Department of Biological Sciences, Korea Advanced Institute of Science and Technology (KAIST), 291 Daehak-ro, Yuseong-gu, Daejeon 34141, South Korea and <sup>3</sup>Center for Virus Research and Testing, Korea Research Institute of Chemical Technology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, South Korea

*Nucleic Acids Res* 2018; 46 (4): 1635-1647. doi: 10.1093/nar/gky039

The authors of the above-cited article request its retraction. The authors have reported that some of the findings and conclusions of the article cannot be relied upon. Specifically, the original data behind Figures 1, 2, 3, 6B, and 6C could not be located and the results could not be replicated. However, the other findings regarding the antiviral and anti-tumoral effect of the synthetic RIG-I ligands still hold true.

The corresponding authors take full responsibility for a failure to follow proper quality control over the production, validation and dissemination of that data. All authors agree with this request and the information provided in this notice.

The Editors commend the authors for being forthcoming and disclosing this issue.

*Authors Contributions:* BC, SK, MK, JL conceived and designed the study, wrote and revised the paper. JL, EP, JM, SS, YJ, JS, DC, KK, JH, ML, YG, DK and MK performed the experiments and/or acquired the data. All authors analyzed the data and approved the manuscript.

---

\*To whom correspondence should be addressed. Tel: +82 42 350 2828; Fax: +82 42 350 5828; Email: byongseok.choi@kaist.ac.kr  
Correspondence may also be addressed to Suk-Jo Kang. Tel: +82 42 350 2611; Fax: +82 42 350 2610; Email: suk-jo.kang@kaist.ac.kr  
Correspondence may also be addressed to Meehyein Kim. Tel: +82 42 860 7540; Fax: +82 42 861 4246; Email: mkim@kriect.re.kr

<sup>†</sup>These authors contributed equally to this work as first authors.

Present addresses:

Mi-Kyung Lee, Disease Target Structure Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, South Korea.

Jiyoun Min, Drug Discovery Center, Life Sciences R&D, E8 Block LG Science Park, 30 Magokjungang 10-ro, Gangseo-gu, Seoul, 07796, South Korea.